Condition: Venous Thromboembolism · Anticoagulant · Elderly · Sponsor: Arianna Anticoagulazione Foundation
The study aims at optimizing extended management of elderly patients (\> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.
This description comes directly from the study's public registry record.
Cristina Legnani, BSc, PhD · 0039 051 2812339 · c.legnani@fondazionearianna.org
Emilia Antonucci, CR · 0039 051 4291116 · e.antonucci@fondazionearianna.org
Always discuss trial participation with your own doctor first.
| Corrado Lodigiani | Rozzano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04257487